title: Intra-aortic balloon counterpulsation as a bridge to heart transplantation does not impair long-term survival.
abstract: OBJECTIVE
  There are few studies of the use of intra-aortic balloon pump (IABP) treatment as a bridge to heart transplantation (HTx). This is the first study to compare long-term clinical and haemodynamic outcomes in IABP-treated HTx patients and electively transplanted patients.
  
  
  RESULTS
  This was a retrospective study of all adult HTx recipients between 2001 and 2007. Thirty-two patients (aged 50 +/- 13 years) treated with IABP, as a bridge to HTx due to severe hypo-perfusion, were compared with 135 electively transplanted patients (aged 54 +/- 11 years). The mean time from onset of IABP to HTx was 21 +/- 16 days. Clinical condition improved during IABP treatment. Serum creatinine decreased from 128 +/- 56 to 102 +/- 29 micromol/L (P < 0.01), aspartate transaminase from 682 +/- 1299 to 63 +/- 89 U/L (P = 0.01), and ALAT from 483 +/- 867 to 126 +/- 284 U/L (P = 0.02). Intra-aortic balloon pump treatment related complications were few. Mortality was similar in the IABP and control groups at 30 days post-HTx (6.2 vs.3.7%, P = 0.54), at 1 year (9.4 vs.11.1%, P = 0.80), and beyond. Long-term clinical and haemodynamic indices were similar in the two groups.
  
  
  CONCLUSIONS
  Intra-aortic balloon pump treatment stabilizes patients in end-stage heart failure, is safe, well tolerated, and is successful in bridging acutely decompensated patients to transplantation. Complications are few and manageable. Following IABP and HTx, short- and long-term survival, biochemical and invasive and non-invasive haemodynamic outcomes were similar to those in electively transplanted patients.
authors.affiliation: Department of Cardiology, Rikshospitalet, N-0027 Oslo, Norway. ola.gjesdal@medisin.uio.no
authors.forename: Ola
authors.initials: O
authors.lastname: Gjesdal
authors.forename: Einar
authors.initials: E
authors.lastname: Gude
authors.forename: Satish
authors.initials: S
authors.lastname: Arora
authors.forename: Torbjørn
authors.initials: T
authors.lastname: Leivestad
authors.forename: Arne K
authors.initials: AK
authors.lastname: Andreassen
authors.forename: Lars
authors.initials: L
authors.lastname: Gullestad
authors.forename: Lars
authors.initials: L
authors.lastname: Aaberge
authors.forename: Harald
authors.initials: H
authors.lastname: Brunvand
authors.forename: Thor
authors.initials: T
authors.lastname: Edvardsen
authors.forename: Odd R
authors.initials: OR
authors.lastname: Geiran
authors.forename: Svein
authors.initials: S
authors.lastname: Simonsen
mesh_terms: D000704:Analysis of Variance; D001219:Aspartate Aminotransferases / Q000097:blood; D016022:Case-Control Studies; D015908:Counterpulsation; D003404:Creatinine / Q000097:blood; D005260:Female; D006333:Heart Failure / Q000628:therapy*; D016027:Heart Transplantation / Q000009:adverse effects / Q000401:mortality; D006439:Hemodynamics; D006801:Humans; D007423:Intra-Aortic Balloon Pumping / Q000009:adverse effects / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D009664:Norway; D011184:Postoperative Period; D012189:Retrospective Studies; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D003404:Creatinine; D001219:Aspartate Aminotransferases